Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Recent Corporate Updates

- ZYNRELEF® unit demand increased 68% in the first quarter compared to the prior quarter - - Centers for Medicare and Medicaid Services approved a 3-year...

Related Keywords

Canada ,United Kingdom ,Heron Biochronomer ,Prnewswire Heron Therapeutics Inc ,European Commission ,Drug Administration ,Hospital Outpatient Department ,Nasdaq ,Exchange Commission ,Centers For Medicare ,European Union ,Health Canada ,Medicaid Services ,Heron Therapeutics Inc ,Care Franchise ,New Drug Application ,Adults Under Review ,Prescription Drug User Fee Act ,Care Franchise Net Product Sales ,Net Product Sales ,Care Franchise Net Product Sales Guidance ,Barry Quart ,Chief Executive Officer ,Investor Relations ,European Economic Area ,Boxed Warning ,Heron Therapeutics ,Private Securities Litigation Reform Act ,Media Contact ,Vice President ,Chief Operating ,Nc ,